Brain tumor drug repurposed: new combo therapy targets recurrent glioblastoma
NCT ID NCT05590689
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests a drug called 5-ALA, already used during brain tumor surgery, combined with radiotherapy for people whose glioblastoma has returned. The main goal is to find the safest dose and schedule of this combination. About 34 participants will be enrolled to see if the treatment is tolerable and may help control the tumor.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
5-Aminolevulinic acid (5-ALA, Gliolan)
What this could lead to
If successful, this could lead to a new treatment option for recurrent glioblastoma that combines a drug with standard radiotherapy to improve outcomes.
What could go wrong
This is an early-phase trial with only 34 participants, so results may not apply widely. The drug is being used in a new way, and side effects like neurological or blood toxicity are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University Hospital Münster, Klinik für Neurochirurgie
RECRUITINGMünster, 48149, Germany
Contact
Contact
Contact